Antibody Response to a Polyvalent Pseudomonas Vaccine in Children with Leukemia


Pseudomonas aeruginosa infection accounts for 30% of gram-negative bacteremias in children with acute leukemia at Memorial Hospital. There is a mortality rate of 87% despite antimicrobial therapy. Previous studies in animals and man following severe burns suggest that P. aeruginosa infection may be subjected to immunological control. Active immunization of 20 leukemic children in bone marrow remission was attempted with a lipopolysaccharide antigen derived from 7 strains of P. aeruginosa (Fisher-Devlin immunotypes). Vaccination consisted of 4 intramuscular injections at weekly intervals. Febrile and local reactions occurred in all, but were not severe enough to discontinue the procedure. The appearance of antibody was demonstrated by 1 to 5 preipitin bands using the Oucterlony immunodiffusion technique. This was correlated with a rise in hemagglutinating antibody titers. Sixteen children demonstrated antibody response within one month, despite the immunosupressive antileukemic therapy that they were receiving. If this antibody proves to be protective against P. aeruginosa infection by further control studies in progress, vaccination of patients early in the course of leukemia would be indicated.

DOI: 10.1203/00006450-197009000-00109

Cite this paper

@article{Haghbin1970AntibodyRT, title={Antibody Response to a Polyvalent Pseudomonas Vaccine in Children with Leukemia}, author={Mahroo Haghbin and Lowell S . Young and D. Armstrong and Megan L Murphy}, journal={Pediatric Research}, year={1970}, volume={4}, pages={461-461} }